K08 CA252619/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2021	2
2022	5
2023	1
2024	2

1

Applications and opportunities for immune cell CAR engineering in comparative oncology.

Rotolo A, Atherton MJ. Rotolo A, et al. Clin Cancer Res. 2024 Apr 4. doi: 10.1158/1078-0432.CCR-23-3690. Online ahead of print. Clin Cancer Res. 2024. PMID: 38573683

2

Quantification of CD3, FoxP3, and granzyme B immunostaining in canine renal cell carcinoma.

Cournoyer A, Amerman H, Assenmacher CA, Durham A, Perry JA, Gedney A, Keuler N, Atherton MJ, Lenz JA. Cournoyer A, et al. Vet Immunol Immunopathol. 2024 May;271:110741. doi: 10.1016/j.vetimm.2024.110741. Epub 2024 Mar 16. Vet Immunol Immunopathol. 2024. PMID: 38520894 Free article.

3

Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients.

Rotolo A, Whelan EC, Atherton MJ, Kulikovskaya I, Jarocha D, Fraietta JA, Kim MM, Diffenderfer ES, Cengel KA, Piviani M, Radaelli E, Duran-Struuck R, Mason NJ. Rotolo A, et al. Cell Rep Med. 2023 Oct 17;4(10):101241. doi: 10.1016/j.xcrm.2023.101241. Cell Rep Med. 2023. PMID: 37852175 Free PMC article.

4

Tumor factors stimulate lysosomal degradation of tumor antigens and undermine their cross-presentation in lung cancer.

Lu Z, Chen J, Yu P, Atherton MJ, Gui J, Tomar VS, Middleton JD, Sullivan NT, Singhal S, George SS, Woolfork AG, Weljie AM, Hai T, Eruslanov EB, Fuchs SY. Lu Z, et al. Nat Commun. 2022 Nov 4;13(1):6623. doi: 10.1038/s41467-022-34428-w. Nat Commun. 2022. PMID: 36333297 Free PMC article.

5

Case Report: Clinical and Serological Hallmarks of Cytokine Release Syndrome in a Canine B Cell Lymphoma Patient Treated With Autologous CAR-T Cells.

Atherton MJ, Rotolo A, Haran KP, Mason NJ. Atherton MJ, et al. Front Vet Sci. 2022 Jul 11;9:824982. doi: 10.3389/fvets.2022.824982. eCollection 2022. Front Vet Sci. 2022. PMID: 35898541 Free PMC article.

6

Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors.

Zhang H, Yu P, Tomar VS, Chen X, Atherton MJ, Lu Z, Zhang HG, Li S, Ortiz A, Gui J, Leu NA, Yan F, Blanco A, Meyer-Ficca ML, Meyer RG, Beiting DP, Li J, Nunez-Cruz S, O'Connor RS, Johnson LR, Minn AJ, George SS, Koumenis C, Diehl JA, Milone MC, Zheng H, Fuchs SY. Zhang H, et al. Nat Cancer. 2022 Jul;3(7):808-820. doi: 10.1038/s43018-022-00383-0. Epub 2022 May 30. Nat Cancer. 2022. PMID: 35637402 Free PMC article.

7

Bite-size introduction to canine hematologic malignancies.

Atherton MJ, Mason NJ. Atherton MJ, et al. Blood Adv. 2022 Jul 12;6(13):4073-4084. doi: 10.1182/bloodadvances.2021005045. Blood Adv. 2022. PMID: 35316831 Free PMC article. Review.

8

Genetic re-direction of canine primary T cells for clinical trial use in pet dogs with spontaneous cancer.

Rotolo A, Atherton MJ, Kasper BT, Haran KP, Mason NJ. Rotolo A, et al. STAR Protoc. 2021 Oct 22;2(4):100905. doi: 10.1016/j.xpro.2021.100905. eCollection 2021 Dec 17. STAR Protoc. 2021. PMID: 34746864 Free PMC article.

9

Increased tumor-infiltrating lymphocyte density is associated with favorable outcomes in a comparative study of canine histiocytic sarcoma.

Lenz JA, Assenmacher CA, Costa V, Louka K, Rau S, Keuler NS, Zhang PJ, Maki RG, Durham AC, Radaelli E, Atherton MJ. Lenz JA, et al. Cancer Immunol Immunother. 2022 Apr;71(4):807-818. doi: 10.1007/s00262-021-03033-z. Epub 2021 Aug 20. Cancer Immunol Immunother. 2022. PMID: 34415404 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

9 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year